

**REFERENCE VALUE CHANGE
REFERRAL**

NOTIFICATION DATE: March 20, 2012

EFFECTIVE DATE: Immediately

PROSTATE-SPECIFIC ANTIGEN, ULTRASENSITIVE
Test ID: FPSAU
Secondary ID: 91817

EXPLANATION: Effective immediately, Test ID FPSAU, referred to LabCorp Burlington, will reflect the following change.

CURRENT REFERENCE VALUE:

0.00-4.00 ng/mL

Roche ECLIA methodology

According to the American Urological Association, PSA should be undetectable after radical prostatectomy. A PSA of less than 0.50 ng/mL (or undetectable) is not likely to be associated with disease recurrence within five years of treatment. Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

NEW REFERENCE VALUE:

0.00-4.00 ng/mL

Roche ECLIA methodology

According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.20 ng/mL or greater followed by a subsequent confirmatory PSA value 0.20 ng/mL or greater.

Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

NOTE: This change may impact test set-up information and could require a change to file definition. Please review the Test Set-Up information for specifics at <http://www.mayomedicallaboratories.com/test-notifications/index.html>.

QUESTIONS: Contact Mary Erath, MML Laboratory Technologist Resource Coordinator
Telephone: 800-533-1710